IP78-22: Real-World Data of Patients Eligible for Adjuvant Pembrolizumab Prior to its National Reimbursement in Italy: Results from an Italian National Cancer Institute Registry

IP78-22: Real-World Data of Patients Eligible for Adjuvant Pembrolizumab Prior to its National Reimbursement in Italy: Results from an Italian National Cancer Institute Registry

Monday, May 18, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)
147B
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!